Why this ASX All Ords stock is soaring 30% on Monday

This stock is starting the week with a bang. But why?

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Imugene Ltd (ASX: IMU) shares are starting the week with a bang.

In morning trade, the ASX All Ords stock is up 30% to 8.1 cents.

Why is this ASX All Ords stock rocketing?

Investors have been fighting to get hold of the clinical stage immuno-oncology company's shares after it announced promising results from a trial.

This trial is the phase 1b clinical trial with azer-cel (an allogeneic off-the-shelf CD19 CAR T) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). It is a type of non-Hodgkin's lymphoma (NHL). All enrolled patients had cancer that had returned following autologous CAR T therapy.

According to the release, 10 patients have been treated to date with Imugene's azer-cel in the Phase 1b DLBCL trial.

Cohort A saw 6 patients treated with azer-cel and lymphodepletion (chemotherapy), whereas cohort B saw 4 patients treated with azer-cel, lymphodepletion, and interleukin 2 (IL-2).

The ASX All Ords stock revealed that there were three complete responses. The first two patients treated in Cohort B achieved a complete response and one patient treated in Cohort A achieved a complete response.

'Delighted'

Imugene's chief medical officer, Paul Woodard, MD, revealed that the company was delighted with the trial results so far. He said:

We are delighted that the first 2 patients in the Cohort B in our azer-cel Phase 1b trial achieved a complete response and continue to maintain their complete responses, one for over 120 days and the other for over 90 days.

All four patients enrolled in Cohort B have failed 4 to 5 prior treatments, including autologous CAR T therapy. All 4 patients remain on the study and given the robust response rates and durability seen to date, we will continue to enrol patients in the azer-cel plus IL-2 cohort and will closely follow all patients for further responses and durability.

This sentiment was echoed by the ASX All Ords stock's managing director and CEO, Leslie Chong. She said:

I am proud of our clinical development team who assessed ways to enhance azer-cel's durability of response, as one of the biggest challenges in CAR T therapy is ensuring that the modified T-cells stay in the body long enough to kill cancer cells.

To maximise the response rates and durability further, we added a very low dose of IL-2 to the regimen in Cohort B. We are pleased with the results, which suggest improved outcomes in patients, and we look forward to amassing more data using this dosing regimen. We will continue to seek biomarker evidence from Cohort B patients that suggest our strategy is improving the performance of azer-cel.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Young investor watching share chart in anticipation
Healthcare Shares

Here's the earnings forecast out to 2029 for CSL shares

This biotech giant could see significant profit growth in the coming years.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

With a projected 7% dividend yield, is the Medibank share price a buy?

Investors may receive very healthy dividends from this stock.

Read more »

Healthcare Shares

Guess which ASX 200 stock is jumping to record high on big European news

What is getting investor excited on Friday? Let's see what is happening.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Goldman Sachs tips ResMed shares to rocket 30% to a record high

The broker is feeling very bullish about the sleep disorder treatment company.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Healthcare Shares

Why CSL shares could be dirt cheap in 2025

Goldman Sachs sees a lot of value in this blue chip stock.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Healthcare Shares

What will happen to the Sigma share price after the Chemist Warehouse merger?

Morgan Stanley analysts explain the default factor that will support the Sigma share price after the merger.

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Broker Notes

Why this top fundie has a 'loss of confidence' in CSL shares

CSL has a lot of broker support right now but Firetrail has an opposing view on the ASX 200 healthcare…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

The market didn't like what this stock had to say this morning...

Read more »